Membrane Type 1 Matrix Metalloproteinase-associated Degradation of Tissue Inhibitor of Metalloproteinase 2 in Human Tumor Cell Lines*

Tissue inhibitor of metalloproteinase 2 (TIMP-2) is required for the membrane type 1 matrix metalloproteinase (MT1-MMP)-dependent activation of pro-MMP-2 on the cell surface. MT1-MMP-bound TIMP-2 has been shown to function as a receptor for secreted pro-MMP-2, resulting in the formation of a trimolecular complex. In the presence of uncomplexed active MT1-MMP, the prodomain of cell surface-associated MMP-2 is cleaved, and activated MMP-2 is released. However, the behavior of MT1-MMP-bound TIMP-2 during MMP-2 activation is currently unknown. In this study,125I-labeled recombinant TIMP-2 (125I-rTIMP-2) was used to investigate the fate of TIMP-2 during pro-MMP-2 activation by HT1080 and transfected A2058 cells. HT1080 and A2058 cells transfected with MT1-MMP cDNA (but not vector-transfected A2058 cells) were able to bind125I-rTIMP-2, to activate pro-MMP-2, and to process MT1-MMP into an inactive 43-kDa form. Under these conditions,125I-rTIMP-2 bound to the cell surface was rapidly internalized and degraded in intracellular organelles through a bafilomycin A1-sensitive mechanism, and125I-bearing low molecular mass fragment(s) were released in the culture medium. These different processes were inhibited by hydroxamic acid-based synthetic MMP inhibitors and rTIMP-2, but not by rTIMP-1 or cysteine, serine, or aspartic proteinase inhibitors. These results support the concept that the MT1-MMP-dependent internalization and degradation of TIMP-2 by some tumor cells might be involved in the regulation of pericellular proteolysis.

[1]  D. Fishman,et al.  Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. , 1999, Cancer research.

[2]  P. Brown Clinical studies with matrix metalloproteinase inhibitors , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[3]  J. Keski‐Oja,et al.  Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. , 1998, The Biochemical journal.

[4]  H. Sato,et al.  Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. , 1998, Journal of biochemistry.

[5]  A. Gulino,et al.  Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. , 1998, Cancer research.

[6]  Y. Okada,et al.  TIMP-2 Promotes Activation of Progelatinase A by Membrane-type 1 Matrix Metalloproteinase Immobilized on Agarose Beads* , 1998, The Journal of Biological Chemistry.

[7]  C. López-Otín,et al.  Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. , 1998, The Biochemical journal.

[8]  J. Foidart,et al.  Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor , 1998, FEBS letters.

[9]  M. Cilli,et al.  TIMP‐2 over‐expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis , 1998 .

[10]  Gillian Murphy,et al.  The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A , 1998, The Journal of Biological Chemistry.

[11]  Y. DeClerck,et al.  Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) Binds to the Catalytic Domain of the Cell Surface Receptor, Membrane Type 1-Matrix Metalloproteinase 1 (MT1-MMP)* , 1998, The Journal of Biological Chemistry.

[12]  M. d’Ortho,et al.  MT1‐MMP on the cell surface causes focal degradation of gelatin films , 1998, FEBS letters.

[13]  Z. Werb ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.

[14]  W. T. Chen,et al.  Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  F. Blasi,et al.  Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes , 1997, The EMBO journal.

[16]  J. Foidart,et al.  Involvement of PA/plasmin system in the processing of pro‐MMP‐9 and in the second step of pro‐MMP‐2 activation , 1997, FEBS letters.

[17]  H. Nagase Activation mechanisms of matrix metalloproteinases. , 1997, Biological chemistry.

[18]  A. Rehemtulla,et al.  Membrane Type Matrix Metalloproteinase 1 Activates Pro-gelatinase A without Furin Cleavage of the N-terminal Domain* , 1996, The Journal of Biological Chemistry.

[19]  H. Sato,et al.  Activation of a recombinant membrane type 1‐matrix metalloproteinase (MT1‐MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)‐2 , 1996, FEBS letters.

[20]  G. Butler,et al.  The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation , 1996, The Journal of Biological Chemistry.

[21]  M. Nakajima,et al.  Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. , 1996, Cancer research.

[22]  J. Westermarck,et al.  Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. , 1996, European journal of biochemistry.

[23]  H. Shimada,et al.  Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. , 1996, Cancer research.

[24]  Y. Okada,et al.  Cell surface binding and activation of gelatinase A induced by expression of membrane‐type‐1‐matrix metalloproteinase (MT1‐MMP) , 1996, FEBS letters.

[25]  S. Weiss,et al.  Transmembrane-deletion Mutants of the Membrane-type Matrix Metalloproteinase-1 Process Progelatinase A and Express Intrinsic Matrix-degrading Activity (*) , 1996, The Journal of Biological Chemistry.

[26]  H. Sato,et al.  MEMBRANE-TYPE MATRIX METALLOPROTEINASES , 2017 .

[27]  S. Zucker,et al.  Activation of human umbilical vein endothelial cell progelatinase A by phorbol myristate acetate: a protein kinase C-dependent mechanism involving a membrane-type matrix metalloproteinase. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[28]  M. Seiki,et al.  Intermolecular Autolytic Cleavage Can Contribute to the Activation of Progelatinase A by Cell Membranes (*) , 1995, The Journal of Biological Chemistry.

[29]  A. Schwartz,et al.  Receptor Cell Biology: Receptor-Mediated Endocytosis , 1995, Pediatric Research.

[30]  R. Giavazzi,et al.  Matrix metalloproteinase inhibition: a review of anti-tumour activity. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  W. Stetler-Stevenson,et al.  gelatinase A/TIMP‐2 imbalance in lymph‐node‐positive breast carcinomas, as measured by RT‐PCR , 1995, International journal of cancer.

[32]  J. Stevens,et al.  Agonist-induced desensitization of dopamine D1 receptor-stimulated adenylyl cyclase activity is temporally and biochemically separated from D1 receptor internalization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Krantz,et al.  Novel indolactam-based inhibitors of matrix metalloproteinases , 1995 .

[34]  J. Foidart,et al.  Cell surface binding of TIMP‐2 and pro‐MMP‐2/TIMP‐2 complex , 1995, FEBS letters.

[35]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[36]  W. Stetler-Stevenson,et al.  Gelatinase A activity directly modulates melanoma cell adhesion and spreading. , 1995, The EMBO journal.

[37]  Hiroshi Sato,et al.  The C-terminal Region of Membrane Type Matrix Metalloproteinase Is a Functional Transmembrane Domain Required for Pro-gelatinase A Activation (*) , 1995, The Journal of Biological Chemistry.

[38]  Y. DeClerck,et al.  Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. , 1994, Cancer research.

[39]  A. Shinagawa,et al.  Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Journal of cell science.

[40]  Motoharu Seiki,et al.  A matrix metalloproteinase expressed on the surface of invasive tumour cells , 1994, Nature.

[41]  L. Liotta,et al.  Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[42]  M. J. Clague,et al.  Vacuolar ATPase activity is required for endosomal carrier vesicle formation. , 1994, The Journal of biological chemistry.

[43]  A. Strongin,et al.  Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. , 1993, The Journal of biological chemistry.

[44]  H. Shimada,et al.  Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. , 1992, Cancer research.

[45]  K. Kato,et al.  Bafilomycin A1 inhibits the targeting of lysosomal acid hydrolases in cultured hepatocytes. , 1991, Biochemical and biophysical research communications.

[46]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[47]  M A Moses,et al.  Identification of an inhibitor of neovascularization from cartilage. , 1990, Science.

[48]  L. Liotta,et al.  Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. , 1989, The Journal of biological chemistry.

[49]  K. Altendorf,et al.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Jensenius,et al.  Eggs: conveniently packaged antibodies. Methods for purification of yolk IgG. , 1981, Journal of immunological methods.

[51]  I. Pastan,et al.  Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. , 1980, The Journal of biological chemistry.

[52]  M. Fini,et al.  Regulation of Matrix Metalloproteinase Gene Expression , 1998 .

[53]  W. Stetler-Stevenson,et al.  Molecular regulation of cellular invasion--role of gelatinase A and TIMP-2. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[54]  L. Liotta,et al.  Cancer invasion and metastasis: positive and negative regulatory elements. , 1991, Cancer investigation.